15 March 2022 - Despite the wonders accomplished by the biopharmaceutical industry in providing us vaccines and therapeutants to get us out of the coronavirus pandemic, this industry – perhaps the most important in the U.S. – continues to be under attack for the cost of drugs.
President Biden highlighted this in his State-of-the-Union address. But, he is not alone. Both sides of the congressional aisle don’t miss an opportunity to attack drug costs and this is only going to get more intense as we move toward the 2022 mid-term elections.